VanEck Pharmaceutical ETF vs VanEck Biotech ETF: Which Fund Is Better for Drug Innovation Profits?
PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper drawdowns.
VanEck Pharmaceutical ETF (PPH) and VanEck Biotech ETF (BBH) are two funds within the same provider that focus on different sectors of the healthcare industry. PPH seeks stability through pharmaceutical leaders, while BBH targets growth potential in biotechnology firms. Despite offering similar costs, the two funds present different risk-reward profiles.
One may cater to risk-averse investors seeking income and lower volatility, whereas the other attracts growth-oriented investors who can tolerate higher price fluctuations. Beta, a measure of price volatility relative to the S&P 500, is calculated from monthly returns over the available fund history, up to five years. The 1-year return represents the total return over the trailing 12 months since the fund's inception.
Additionally, dividends yield, representing the trailing-12-month distribution yield as of September 10, 2026, can be compared between the two ETFs.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
